PRESS RELEASES & ARTICLES

Current Openings at Calvert Research
Calvert is currently recruiting an experienced Chief Science Officer (MD) responsible to direct a staff of project managers. This person will need at least 15 years experience in preclinical and early clinical development leadership (pre-phase 3). A broad therapeutic background is preferred.

In addition, Calvert is hiring project managers at a variety of levels. Although PhD candidates are preferred, applicants with a MS/BS and 8+ years experience in pharmaceutical drug development will also be given consideration (PMP preferred).

Contact Jeff Tippett (jeff.tippett @ calvertholdings.com or 919/854-4453) for more information...Read story »

CureDM’s Diabetes Therapy Achieves Major Development Milestone
Wynnewood, PA (April 30, 2008). CureDM, Inc., a biopharmaceutical company developing new therapies to prevent, ameliorate, or reverse both type 1 and 2 diabetes, announces successful stabilization of their patented Human proIslet Peptide (HIP). By stabilizing HIP, CureDM improved its bioavailability. Recently completed studies indicate that human dosage requirements may be as much as 100-fold lower than the native form...Read story »

Lankenau Hospital Physicians Research
a New Treatment for Diabetes
Wynnewood, PA - March 20, 2007: Two endocrinologists at Lankenau Hospital in collaboration with the Lankenau Institute for Medical Research (LIMR) are conducting groundbreaking research they hope will produce a new treatment for diabetes, a disease that affects 20.8 million adults and children in the United States... Read story »

CureDM: A Novel Approach to Diabetes
New Jersey TechNews, December 2006/January 2007 Edition
CureDM is crossing disciplines to bring a novel approach to the treatment of diabetes. Applying new proteomics methods to physiology of diabetes to integrate clinical medicine with the frontiers of life science research has created this bold new approach... Read story »